Long-term outcomes in 45,X/46,XY mosaicism: a 30-year retrospective study in Hong Kong
Annals of Pediatric Endocrinology & Metabolism · 30.06.2026 · 31 (3) · 168-177
DOI: 10.6065/apem.2550284.142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Pediatric Endocrinology & Metabolism, erschienen am 30.06.2026. Verfasst von Sarah Wing Yiu Poon und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, Hong Kong. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Purpose
45,X/46,XY mosaicism is a rare subset of sex chromosome abnormalities within the spectrum of differences of sex development. This study aimed to evaluate the long-term outcomes in a group of individuals with 45,X/46,XY mosaicism over a 30-year period.
Methods
A retrospective review was performed including 68 patients diagnosed from January 1990 to December 2023 at a tertiary unit. Cytogenetic analysis, patient demographics and various health outcomes were examined.
Results
Thirty-five patients were raised as females and 33 were raised as males. Fifteen patients were found to have 45,X/46,XY mosaicism prenatally. The prevalence of gonadal tumor was 17.6% among phenotypic females and 38.5% in males with abnormal genitalia, whereas no tumors were detected in males with normal genitalia. The mean external genitalia score was significantly lower in males with gonadal tumors compared to those without (6.6 vs 10.4, P=0.002). For females, while most gonadal tumors were identified in those who had gonadectomy at pubertal age (5 of 6, 83.3%), gonadal tumors were also detected in very young children (1.3 years old). There was no significant improvement in height in those treated with growth hormone therapy and final adult height remained suboptimal (overall final adult height z-score -2.6±1.2). Adherence to surveillance for associated systemic comorbidities was inconsistent.
Conclusion
Gonadal tumor risk is higher in less masculinized males, while females may develop tumors across a wide age range. The long-term efficacy of growth hormone therapy in these patients remains unclear. Our findings emphasized the need for individualized surveillance in this population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, Hong Kong.
- Department of Clinical Genetics, Hong Kong Children's Hospital, Hong Kong.
- Department of Obstetrics and Gynaecology, Tuen Mun Hospital, Hong Kong.
- Department of Clinical Genetics, Hong Kong Children's Hospital, Hong Kong. lukhm@ha.org.hk.
Zitieren
APA
Poon, S. W. Y., To, S. W. Y., Siu, L. L. P., Cheng, S. S. W., Ho, S. K. L., Pang, G. S. W., So, P. P. L., Tung, J. Y. L., & Luk, H. M. (2026). Long-term outcomes in 45,X/46,XY mosaicism: a 30-year retrospective study in Hong Kong. Annals of Pediatric Endocrinology & Metabolism, 31(3), 168-177. https://doi.org/10.6065/apem.2550284.142
Vancouver
Poon SWY, To SWY, Siu LLP, Cheng SSW, Ho SKL, Pang GSW, et al. Long-term outcomes in 45,X/46,XY mosaicism: a 30-year retrospective study in Hong Kong. Annals of Pediatric Endocrinology & Metabolism. 2026;31(3):168-177. doi:10.6065/apem.2550284.142
BibTeX
@article{Poon2026,
author = {Poon, Sarah Wing Yiu and To, Sharon Wing Yan and Siu, Lisa Lai Ping and Cheng, Shirley Sze Wing and Ho, Stephanie K L and Pang, Gloria Shir Wey and So, Pauline Po Lam and Tung, Joanna Yuet Ling and Luk, Ho-Ming},
title = {Long-term outcomes in 45,X/46,XY mosaicism: a 30-year retrospective study in Hong Kong},
journal = {Annals of Pediatric Endocrinology & Metabolism},
year = {2026},
volume = {31},
number = {3},
pages = {168--177},
doi = {10.6065/apem.2550284.142}
}
EUVIMED